SCHEMBL1639465

SCHEMBL1639465

Clc1nc(Cl)nc(OCc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.49
ALOX5 P09917 1/20 0.44
PTGS2 P35354 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 2/20 0.43
CYP1A2 P05177 2/20 0.42
LMNA P02545 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
CYP2C19 P33261 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL578063 0.96 PIN1 (0.49) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL32688297 0.88 MAOB (0.44) PIN1PTGS2L3MBTL1TSHRCYP1A2
SCHEMBL17066149 0.88 L3MBTL1 (0.45) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL16086043 0.86 PIN1 (0.43) PIN1ALOX5PTGS2L3MBTL1CYP1A2
SCHEMBL11009131 0.85 TSHR (0.52) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL17563554 0.84 MAOB (0.47) PTGS2L3MBTL1LMNAPTGS1MAPT
SCHEMBL28776503 0.83 PIN1 (0.49) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL10639701 0.83 MAPT (0.46) PIN1L3MBTL1MAPTMAPK1TDP1
SCHEMBL8670167 0.82 PIN1 (0.48) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL9370072 0.81 PIN1 (0.51) PIN1ALOX5RAB9ASMN1; SMN2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946475-B2 Processes for preparing a polymeric compound CELLCEUTIX CORPORATION (US) 2015-02-03 US claimed
EP-1912951-B1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA (DE) 2010-01-06 EP claimed
US-7608722-B2 Preparation of 1,7,′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-27 US claimed
EP-1912951-A1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-04-23 EP claimed
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-15 US claimed
WO-2007009967-A1 PREPARATION OF 1,7′-DIMETHYL-2′-PROPYL-2,5′-BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-25 WO claimed
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 US disclosed
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT INNOVATION PHARMACEUTICALS INC. (US) 2023-10-05 US disclosed
US-11666571-B2 Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract INNOVATION PHARMACEUTICALS INC. (US) 2023-06-06 US disclosed
EP-3258927-B1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT INNOVATION PHARMACEUTICALS INC (US) 2021-06-09 EP disclosed
US-20200368232-A1 Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract INNOVATION PHARMACEUTICALS INC. (US) 2020-11-26 US disclosed
US-20190071406-A1 METHOD FOR PRODUCING ISOCYANURIC ACID DERIVATIVE HAVING TWO HYDROCARBON GROUPS NISSAN CHEMICAL CORPORATION (JP) 2019-03-07 US disclosed
EP-3258927-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT Innovation Pharmaceuticals Inc. (US) 2017-12-27 EP disclosed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO disclosed
EP-0258391-A1 USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD RHONE POULENC NEDERLAND B.V. (NL) 1988-03-09 EP disclosed
WO-1987004321-A2 USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD RHONE-POULENC NEDERLANDS B.V. (NL) 1987-07-30 WO disclosed
US-4234341-A s-Triazine, process for producing it and its use for fireproofing polyester fiber materials CIBA-GEIGY CORPORATION (US) 1980-11-18 US disclosed
US-4165435-A SULFAMOYL OR SULFAMOYL-AMINO SUBSTITUTED; POLYESTERS CIBA-GEIGY CORPORATION (US) 1979-08-21 US disclosed
US-4086204-A LIGHT STABILIZERS CHIMOSA CHIMICA ORGANICA S.P.A. (IT) 1978-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200368232-A1 Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract FABP2, HMGB1, MASP2 PIN1 3129/4885ALOX5 1447/4885PTGS2 647/4885
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK PIN1 4666/4885ALOX5 719/4885PTGS2 1340/4885
US-11666571-B2 Host defense protein (HDP) mimetics for prophylaxis and/or treatment of inflammatory diseases of the gastrointestinal tract FABP2, HMGB1, MASP2 PIN1 3129/4885ALOX5 1447/4885PTGS2 647/4885
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) PNMT, PAM, PAH PIN1 1448/4885ALOX5 1464/4885PTGS2 1105/4885
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 PIN1 3882/4885ALOX5 3990/4885PTGS2 2133/4885
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT FABP2, HMGB1, MASP2 PIN1 3129/4885ALOX5 1447/4885PTGS2 647/4885
US-20190071406-A1 METHOD FOR PRODUCING ISOCYANURIC ACID DERIVATIVE HAVING TWO HYDROCARBON GROUPS PAH, AHR, CYP1B1 PIN1 1073/4885ALOX5 888/4885PTGS2 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.